Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 EV-to-OCF is 50.89 as of Jul. 14, 2026, which is 447% above its 10-year median of 9.30. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Labiana Health ranks worse than 88.1% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Labiana Health's Enterprise Value is €86.46 Mil.
Labiana Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €1.70 Mil. Therefore, Labiana Health's EV-to-OCF for today is 50.89.
The historical rank and industry rank for Labiana Health's EV-to-OCF or its related term are showing as below:
XMAD:LAB'
s EV-to-OCF Range Over the Past 10 Years
Min: -33.54 Med: 9.3 Max: 51.39
Current: 51.39
During the past 6 years, the highest EV-to-OCF of Labiana Health was 51.39. The lowest was -33.54. And the median was 9.30.
XMAD:LAB's EV-to-OCF is ranked worse than 88.1% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.58
vs XMAD:LAB: 51.39
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Labiana Health's PE Ratio (TTM) for today is calculated as:
Labiana Health's share price for today is €6.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.352.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Labiana Health EV-to-OCF Related Terms
Labiana Health EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Labiana Health's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Labiana Health's EV-to-OCF falls into.
Labiana Health's current Enterprise Value is €86.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €1.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a EV-to-OCF of 50.89 as of Jul. 14, 2026. This is 447% above median its historical median of 9.30. According to the industry distribution chart, Labiana Health ranks #888 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 88.1%.
Is Labiana Health's EV-to-OCF too high?
Labiana Health's current EV-to-OCF of 50.89 is 447% above median its 10-year median of 9.30. The Drug Manufacturers industry median EV-to-OCF is 10.58. Labiana Health's value of 50.89 is 381% above this industry median. Based on the distribution chart, Labiana Health ranks #888 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #888 out of 1008 companies for EV-to-OCF. This places Labiana Health in the lower half of its industry. The industry median EV-to-OCF is 10.58. Labiana Health's value of 50.89 is 381% above this benchmark. While the company's 10-year median is 9.30 vs. the industry median of 10.58, Labiana Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.58, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current EV-to-OCF of 50.89 is 381% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current EV-to-OCF is 50.89, which is 447% above median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.60 — trading 83.8% above its estimated fair value. The current EV-to-OCF is 50.89, which is 447% above median its 10-year median of 9.30 and 381% above the Drug Manufacturers industry median of 10.58. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current EV-to-OCF is 50.89 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.60 is trading 83.8% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
EV-to-OCF: 50.89 (447% above median its 10-year median of 9.30)
GF Value™: €3.59 vs. price of €6.60 (83.8% above fair value)
Industry Position: 381% above the Drug Manufacturers median (#888 of 1008)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
